Evidence map›Paper›PMID 36750608›Full record

Trial reportHypertension research : official journal of the Japanese Society of Hypertension2023

Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.

Kentaro Kohagura, Sunao Kojima, Kazuaki Uchiyama, Naoto Yokota, Eiichi Tokutake, Yutaka Wakasa, Shinya Hiramitsu, Masako Waki, Hideaki Jinnouchi, Hirokazu Kakuda and 12 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Hypertension research : official journal of the Japanese Society of Hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Current updates and future perspectives in uric acid research, 2024.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 1 country.

Kentaro KohaguraDialysis Unit, University of the Ryukyus Hospital, Nishihara, Japan. kohagura@med.u-ryukyu.ac.jp.
Sunao KojimaDepartment of Internal Medicine, Sakurajyuji Yatsushiro Rehabilitation Hospital, Yatsushiro, Japan.
Kazuaki UchiyamaUchiyama Clinic, Joetsu, Japan.
Naoto YokotaYokota Naika, Miyazaki, Japan.
Eiichi TokutakeTokutake Iin, Kawaguchi, Japan.
Yutaka WakasaWakasa Medical Clinic, Kanazawa, Japan.
Shinya HiramitsuHiramitsu Heart Clinic, Nagoya, Japan.
Masako WakiShizuoka City Shizuoka Hospital, Shizuoka, Japan.
Hideaki JinnouchiJinnouchi Hospital Diabetes Care Center, Kumamoto, Japan.
Hirokazu KakudaKakuda Iin, Kahoku, Japan.
Takahiro HayashiHayashi Medical Clinic, Sakai, Japan.
Naoki KawaiKawai Naika Clinic, Gifu, Japan.
Masahiro SugawaraSugawara Clinic, Tokyo, Japan.
Hisao MoriFuji Health Promotion Center, Fuji, Japan.
Kenichi TsujitaDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Kunihiko MatsuiDepartment of Community, Family, and General Medicine, Kumamoto University Hospital, Kumamoto, Japan.
Ichiro HisatomeInstitute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, Yonago, Japan.
Yusuke OhyaDepartment of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine, Okinawa, Japan.
Kazuo KimuraDivision of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.
Yoshihiko SaitoDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.
Hisao OgawaKumamoto University, Kumamoto, Japan.
Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators
Kumamoto University · JPUniversity of the Ryukyus · JPHayashi Eye Hospital · JPKanazawa Medical Center · JPKumamoto University Hospital · JPNagoya Heart Center · JPNara Medical University · JPShizuoka City Hospital · JPTokiwa Park · JPTottori University · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effect of urate-lowering on renal outcomes in patients at high-risk for cardiovascular disease with hyperuricemia without gout is not known. We conducted a post hoc analysis of a randomized trial (Febuxostat for Cerebral and　CaRdiorenovascular Events PrEvEntion StuDy [FREED]). The FREED trial enrolled 1070 asymptomatic, hyperuricemic elderly patients with at least one risk factor for cardiovascular disease, divided into febuxostat (n = 537) and non-febuxostat (n = 533) groups. We compared the effect of these treatments on renal outcomes including 40% decline in estimated glomerular filtration rate, new onset of microalbuminuria and development or worsening macroalbuminuria. The relative risk of developing or worsening macroalbuminuria was 56% lower in the febuxostat group (hazard ratio, 0.44; 95% CI, 0.24-0.82; P = 0.0098). However, the risks for other outcomes were comparable. In patients with asymptomatic hyperuricemia without gout, febuxostat reduces the risk of development or worsening of macroalbuminuria.

Indexed as

Cardiovascular DiseasesGoutHyperuricemiaAgedFebuxostatGout SuppressantsHumansTreatment OutcomeUric AcidFebuxostatGout SuppressantsUric AcidAlbuminuriaChronic kidney diseaseFebuxostatHyperuricemiaRandomized clinical trial

Identifiers

PMID36750608
OpenAlexW4319441518

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.